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Management of Hypertension in Women of Childbearing Age
Abstract
This literature review was based on a successful completion of an Objective Structured
Clinical Examination (OSCE) and oral defense. A case report was analyzed, and the topic,
“Management of hypertension in women of childbearing age,” was developed. Research was
done using databases such as CINAHL, PubMed, and Cochrane. Keywords used included
“Management,” “hypertension,” and “childbearing women,” filtered by publication date range
from 2001 to 2016. Recommendations from the 2014 Eighth Joint National Committee (JNC8),
the Unites States Preventive Service Task Force (USPSTF), the American Society of
Hypertension (ASH), and the international Society of Hypertension (ISH) were reviewed. The
literature used in these articles and guidelines was consistent with respect to the definition of
hypertension, treatment, and management both for women of childbearing age and pregnant
women. ASH and ISH, however, have issued clinical practice guidelines for the management of
hypertension that differ in some areas from JNC8 panel’s recent clinical guidelines. In a
Cochrane review of clinical guidelines related to pharmacological management of hypertension
in women of childbearing age, the following observations were made:


Women may require different hypertensive regimes in association to differences in the
progression of hypertension.



Pre-menopausal women often require different medication regimes due to the potential
for pregnancy, being pregnant, and breastfeeding.



The use of contraceptive and hormones replacement therapy also complicates the disease
and its management. Some of the hypertensive medications do have adverse effects,
many are particularly problematic to women (Dubrey, 2013).
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Background and Rationale
Hypertension is defined as consistent blood pressure (BP) greater or equal to 140/90mm
Hg, regardless of gender differences or race; this standard is used in classification of
hypertension considering the epidemiological relationship between increased blood pressure and
cardiovascular disease (Magee, 2001). Blood pressures have various stages for men, women, and
different races. Stage 1 hypertension is BP > 140/90mm Hg, stage 2 is a BP >160/100mm Hg,
and severe BP is defined as systolic pressure > 180mm Hg and/or diastolic BP >110mm Hg.
(Dubrey, 2013). These stages correlate with the treatment regimen ultimately prescribed. For
example, in pre-hypertensive stage, lifestyle modification is strongly recommended, whereas
pharmacologic treatment is required for patients diagnosed with stage 2 or severe hypertension
(Nguyen, Dominguez, Nguyen, and Gullapalli, 2010).
Despite the increased proportion of women worldwide (approximately 25% in 1975–
1980 to about 40% in 2000–2005), few studies or clinical trials focus attention on women
subjects (Ljungman, Mortensen, Kahan, and Manhem, 2009). Women of childbearing age
warrant a special attention from clinicians due to possible reproductive goals and potential risks
of exposing unborn fetus to harmful side effects of pharmacologic treatments. In general, a
diagnosis of hypertension increases an individual’s risk of cardiovascular disease, such as stroke
and renal failure. For women of childbearing age, hormonal changes, hormone-based
contraception, replacement therapy, and pregnancy contribute to the different impact of
hypertension on women that calls for differential modification and management strategies. It is
important, for example, for a clinician to be aware of a woman’s method of birth control when
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having patients of this age group and gender because some contraceptives are known to elevate
BP levels (Magee, et. al, 2010).
Risk of an unplanned pregnancy is another reason to monitor women of childbearing age
carefully. According to McGee (2001), 50% of pregnancies are unplanned, and inadvertent early
exposure to antihypertensive agents, capable of acting as teratogens, may lead to birth defects.
ACE inhibitors and angiotensin receptor antagonists are examples of teratogenic agents that
women who are pregnant or plan to become pregnant, should avoid. The dilemma for patients,
doctors, and clinicians is that these medications are useful for maintaining health for some
women of childbearing age with essential hypertension. In such circumstances, clinicians should
strongly encourage women to seek alternative methods of BP management before and during
pregnancy and while breastfeeding (formula feeding may have to be prescribed if a mother must
resume therapy soon after delivery). Treatment goals of hypertension in women of childbearing
age should necessarily aim to decrease cardiovascular risk as well as prevent pre-eclampsia and
eclampsia and improve maternal and fetal outcomes for pregnant women; this is effective with
absolute control of blood pressure levels, as well as a reduction of the risk of hypertensionrelated damage to target organs (Brown & Garovic, 2014).
In addition to presenting a case report of the clinical assessment of a woman with
hypertension, this report will attempt to use the literature to answer the following questions:
1. What is the prevalence of hypertension among women of childbearing age?
2. What are the risk factors and co-morbidities at stake?
3. What are the practice guidelines for managing the hypertension of women of childbearing
age?
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4. What does the clinical or pharmacological literature suggest about appropriate ways of
managing hypertension of women of childbearing age?
The paper concludes by summarizing the clinical significance of studying women of
childbearing age, defined as women ranging from age 15 to 44, who may or may not become
pregnant, and the major learning points for the clinician presented with the responsibility of
managing hypertension for women of this age group.
Prevalence and Incidence
In a review article, Moodley warned that the “incidence of hypertension in young women
is likely to increase in the near future because of the rising rates of the metabolic syndrome,
obesity and dyslipidaemia worldwide. Consequently, more women will be on antihypertensive
agents, which have the potential for teratogenicity” (Moodley, 2011, p.330). A US study reports
that the prevalence of hypertension among women of childbearing age, 20-44years, is 7.7%
(Dubrey, 2013). One to six percent of women aged 18 to 44 years have hypertension, though
there is variation of hypertension among different ethnic groups. Women of African-American
descent have a higher prevalence of high blood pressure than any other race, with incidence
starting at younger age and being more severe (Dubrey, 2013). Furthermore, according to
Dubrey, hypertension is one of the most complicated medical conditions that affect about 10%15% of pregnant women. Complications of hypertension in pregnant women, which includes
pre-eclampsia, eclampsia, cardiovascular problems, and maternal and fetal complications occur
in about 3%-5% of pregnancies (Dubrey, 2013). Young women or premenopausal women tend
to have low blood pressure, and as a result, are at low risk of cardiovascular disease and are less
in need of being placed on anti-hypertensive medications (Dubrey, 2013).
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Risks Factors

Many risk factors predispose women of childbearing age to high blood pressure; these
include obesity, family history, and unhealthy lifestyle. The most significant contribution to
hypertension in women is obesity, and there is an increased relationship of BP and BMI >25
(Dubrey, 2013). Other contributing factors are lack of exercise, (with only 24% of women
exercising for the recommended 30 minutes a day), and the impact of increased salt intake on
high BP. Another risk factor is diabetes, which can coexist or exacerbate hypertension (Dubrey,
2013).

Case Report
This segment describes a clinical assessment of a woman in her late forties, who has been
diagnosed with hypertension and treated with ACE inhibitor to control her blood pressure.
During the “clinical visit” in question, the patient reported excessive and nagging cough which
began after she started a prescribed medication, lisinopril, for her BP. She routinely did homebound monitoring of blood pressure and noted it was consistently high. During the encounter,
she was diagnosed with ACE inhibitor-induced cough, and treatment modalities were initiated.
The details of her assessment appointment cover, the history of her illness, past medical history,
family and social history, system review, the results of her physical examination and the
recommended care plan following diagnosis.
Patient Description and History of Present Illness (HPI)
On February 5, 2016, this student-clinician evaluated a 48-year old Black American
female “patient” whose chief complaint was a “nagging cough” that has lasted for two weeks.
During routine questioning, this student-clinician discovered the patient has a family history of
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hypertension and a recently diagnosed high blood pressure—she reported being diagnosed with
high blood pressure about 6 weeks ago. The patient described how she was randomly checking
her blood pressure at home with her father in-law’s BP-monitoring machine when she noticed
that her BP was elevated. She subsequently went to the clinic to have it checked, and it was
indeed elevated. After initial lifestyle modification regimen failed to yield desired BP levels, she
was prescribed Lisinopril, 20 mg daily. Patient came to the “clinic” for additional assessment of
February 5th because she had been having nagging dry coughs, day and night, since she started
taking the medication: “I have this nagging cough for 2 weeks now,” she stated. She also
reported that nothing made it better or worse; coughing was continuous, woke her up from sleep,
and interfered with her daily activities. Patient stated that the pharmacist told her the cough was
a possible side effect of the BP medication, and patient wondered if that could be the cause of
her cough. Further review of her of medical chart revealed the following details:
Past Medical History:
Medical: Hypertension
Surgical:
1. Cholecystectomy
2. Tubal Ligation
Medications:
1. Lisinopril 20 mg daily
2. Tylenol as needed
3. Women’s MTV daily
Allergies: NKDA
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Family History:
1. Father: Type 2 diabetes, high blood pressure, high cholesterol and heart stent.
2. Mother: Osteoporosis and high blood pressure
3. Brother: High cholesterol and high blood pressure
4. Sister: Breast Cancer
Socio-economic History: Patient does not exercise regularly. She does desk work. She denies
smoking or using illicit drugs, although she drinks 1 to 2 glasses of wine most evening.
Screening:
1. Pap Smear: 3 years ago
2. Mammogram every year
Review of System:
1. General: Denies fever, malaise or unexplained weight changes.
2. HEENT: Denies headaches or recent head injury
3. Cardiovascular: Denies chest pain or heart palpations. No history of heart murmurs.
4. Respiratory: Denies dyspnea, no chest tightness.
5. Gastrointestinal: Denies nausea, vomiting, and constipation
6. Neurologic: Denies headaches, syncope or seizures.

Physical Examination Results, Assessment, and Plan of Care
Physical Examination:
A complete examination on the day of her appointment with this student clinician
revealed the following physical conditions:

7
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1. General: Alert and oriented x4. Good historian and answer questions appropriately.
Good hygiene.
2. Vitals: BP 142/78: P 72: R14: BMI 27 kg/m2
3. HEENT: Atraumatic, no glasses, PEARL, EOMs intact Ears symmetrical, no tenderness
or discharge.
4. Respirations: Lungs sound clear all fields; no crackles or wheezing
5. Cardiovascular: Regular heart rate with no murmurs. No peripheral edema.
6. Neurological: Cranial nerve I-XII grossly intact.
7. Differential Diagnosis:
a. Upper respiratory infection
b. Asthma
c. ACE induced cough.
8. Labs/Imaging:
Basic Metabolic Panel (BNP) and Complete blood Count (CBC). WNL
a. BMP: BUN 28 mg/dL, Na 140 mmol/L, K 3.9 mmol/L, Cl 105 mmol/L, CO2 27
mmol/L, Glucose (non fasting) 120 mg/dL, Creatine 0.9 mg/dL, calcium 8.8
mg/dL, MDRD eGFR >60
b. WBC: (K/MCL) 9.0, RBC (M/MCL) 48, Platelet (K/MCL) 163, Hgb (G/DL)
12.5, Hct (%) 45, MCV (FL) 88, MCHC (G/DL) 34, MCH (PG) 32.
Assessment:
1. ACE inhibitor-induced cough;
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2. Patient’s symptoms result most likely from the side effects from Lisinopril ACE
inhibitor. Patient’s symptoms started after she begins taking the medications. Her
blood pressure is somewhat reduced but likely not tolerating the medication.
Care Plan:
1. Discontinue Lisinopril 20 mg PO daily.
2. Start Losartan 50 mg PO daily for hypertension
3. Encourage patient to:
a. exercise daily to mitigate against the effects of a sedentary desk job
b. Monitor blood pressure at home
c. Report any side effect of medication
d. Call if symptoms persist
e. Report back to the clinic within 2 weeks.

Literature review
The main emphasis of this literature review is to examine evidenced-based
recommendations for the management of hypertension in women of childbearing age. In addition
to early or routine screening, the two main interventions for the control and management of high
blood pressure in women of childbearing age are lifestyle modification and drug therapy.
Early Screening
Early or routine is designed to identify pre-hypertensive problems before they become
magnified. Hypertension disorder in pregnancy is a major cause of maternal, fetus, and neonatal
morbidity and mortality. Women should be assessed and evaluated for their blood pressure status
before conception, and for hypertensive women planning to become pregnant, it may be advised
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before conception to change their antihypertensive medications which are known to be safe
during pregnancy (Dubrey, 2013).
The USPSTF (2011) recommends screening for blood pressure in adults age 18 and over.
Strategies include ambulatory blood pressure monitoring and homebound blood pressure
monitoring. Ambulatory monitoring measures blood pressure every 20-30 minutes over the
course of 24 to 48 hours of normal activities. The 2014 Eighth Joint National Committee (JNC8)
has specific recommendations regarding effective methods of measuring blood pressure. These
include appropriate cuff size, patient position, and multiple readings (JNC8, 2014). White coat
hypertension, which may be noted in some women at earlier stages of pregnancy, can be
mistaken for gestational hypertension (Brown & Garovic, 2014). Proper recording of blood
pressure helps to identify women with white coat hypertension.
Lifestyle Modification Therapy
Once a diagnosis has been made, the primary goals for blood pressure intervention are to
help patients maintain blood pressure control with lifestyle modifications (fostering selfmanagement skills) and through drug therapy (Hannah & Hyeoun, 2016). According to the 2014
Evidence-Based Guidelines adopted in 2014 by the Joint National committee (JNC8) for the
management of high blood pressure in adults 18 years and older, lifestyle modification should be
recommended as the first line of management of high blood pressure. The second step is setting a
blood pressure target based on patient’s age, co-morbidities such as diabetes mellitus, and
chronic renal status, and obtaining this therapeutic target through drugs management.
Lifestyle modification is worth considering because it helps reduce BP, improve the
effectiveness of anti-hypertensive medications or eliminate the need for medication altogether.
(Magee, 2001). Lifestyle modifications that must be adhered to are smoking cessation,
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decreased salt intake, exercise, bodyweight reduction, and moderation in alcohol consumption
(Magee, 2001).
Since obesity triples the risk of developing hypertension in women, patients who are
obese should be asked about their diet and exercise pattern and offered education and written
guidance. Increase consumption of fruit and vegetables and reduction in fat content can improve
the patient’s diet and impact risk factors for hypertension (charlotte, 2013).
Reduction in sodium consumption can decrease the risk of hypertension. Patients are
encouraged to reduce their sodium intake or follow a cardiac diet. Smoking cessation is of
utmost importance. Tobacco use can cause vascular disease and contribute to hypertension.
Clinicians should advise cessation and offer treatment (Easton, 2006). These recommendations
have proven to be therapeutic in reducing high blood pressure in young women.
Lifestyle modifications are also used to help address cardiovascular risk factors.
According to Magee (2001), smoking cessation, moderate alcohol use, and reduction in BMI
would help lower blood pressure, eliminate or decrease use of anti-hypertensive medications, and
enhance effectiveness of anti-hypertensive medications (Magee, 2001).
Pharmacology Therapy
Various factors are considered before initiating medications therapy for patient who
needs anti-hypertensive treatments. Women of childbearing age require modification to
hypertensive drugs therapy at different stages of their lives because of concomitant therapies,
including contraceptive, hormonal therapies, and other women-related issues (Dubrey, 2013).
Clinicians should consider the cost of medications, patient preference, history of adverse
effects, potential interactions with other medication the patient is taking, pregnancy, and other
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co-morbidities (Magee, 2001). The choice of therapy should be based upon efficacy, safety, cost,
convenience, and other patient-related factors such as dosing regimen and delivery.
The 2014 National Joint Committee (JNC8) recommended diuretics, calcium channel
blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor
blocker (ARB) as first line of treatment, especially when there are associations with other
diseases. Some patients may need two or more anti-hypertension medication for lowering blood
pressure. However, women of childbearing age, or those planning to become pregnant, are
advised to avoid ACE inhibitors and angiotensin II receptor blockers (ARB) due to potential fetal
effects. Beta- blockers should be used in premenopausal women as alternative to CCBs, ACE
inhibitors, or ARBs (Nguyen et al, 2010). According to the study by Simon Dubrey, the
percentage of women who developed ACE-induced cough is higher in women than men, with
some other studies indicating that women are twice as affected as men (Dubrey, 2013).
Diuretics
Diuretics are widely used among premenopausal or non-pregnant women mostly because
of their low cost and availability, and it is considered effective with major cardiovascular
problems. Diuretics can be divided into three groups: Thaizide, loop, and potassium-sparing
diuretics. Diuretics reduce blood pressure by promoting natriuresis and reducing intravascular
volume. Thaizides act to inhibit the absorption of sodium and chloride in the distal convoluted
tubule. Thaizides are particularly beneficial for stroke, heart failure, and coronary artery disease
(CAD) patients. Diuretics are shown to be effective for black women and in combination with
beta-blocker or ACE inhibitors. The side effect of diuretics is hypokalamia, and impaired
glucose tolerance can be reduced with medication dosage management, such as using low doses
not more than 25 mg of hydrochlrothiazide (Magee, 2001). According to Magee (2001), early
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studies reported concerns that thaizide diuretics may cause neonatal thrombocytopenia, but no
evidence of increase of this problem of neonatal exposed to thaizides diuretics were found.
Despite early concern of neonatal effect, Nguyen et al., (2010) found no negative effect on fetal
growth as early believed.
Beta-Blockers
Like diuretics, beta-blocker are inexpensive, readily available and frequently used for the
treatment of hypertension in nonpregnant women. Magee’s (2001) study has shown that these
class of medication are effective in decreasing cardiovascular risk problem, renal sympathetic
output, rennin production and sodium excretion, and cardiac output as a result of reducing heart
rate. Beta- blockers are not effective for the management of hypertension in black race because
of low rennin hypertension (Magee, 2001). Atenolol is another popular beta-blocker that is
widely used because it is effective with cardiovascular-risk patient. Some of the side effects of
beta-blockers are bronchospasm and lethargy; some patient may experience poor sleep (Magee,
2001).
ACE inhibitors
ACE inhibitors are effective in lowering blood pressure by inhibiting the conversion of
the inactive angiotensin I to the active angiotensin II, and as a result decreasing the production of
angiotensin II and aldosterone, to produce vasodilation and increase bradykinins and
prostaglandins (Nguyen et al., 2010). ACE inhibitors are widely tolerated medications and are
now popularly used for women of childbearing age. ACE inhibitors are also a preferred choice to
ARB due to cost effectiveness; ARB should be used in place of ACE only if there are intolerance
with ACE inhibitors, such as cough and angioedema (Nguyen et al., 2010). ACE inhibitors have
some adverse effects, including dry cough—it may cause renal failure in some patient with
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kidney disease (Magee, 2001). It is not recommended that ACE inhibitors be used during second
and third trimester of pregnancy due to their association with fetopathy. Studies have shown use
of this medication may cause fetal distress, fetal death, oligohydramnios. They may also cause
such neonatal issues as renal failure, pulmonary hypoplasia, joint contractures, and intrauterine
growth restriction. Long-term use of ACE inhibitors increases the risk of fetal physiology and
ACE inhibitors and angiotensin receptor antagonist in association should be stopped during
pregnancy (Magee, 2001).
Calcium Channel blockers
Calcium channel blockers (CCBs) are anti-hypertensive medications used to lower blood
pressure; they are widely used for non-pregnant women, though nifedipine has been prescribed
in later pregnancy. Calcium channel blockers act by preventing calcium from entry into vascular
smooth muscles, leading to vasodilation and reduction in vascular contractility. The literature has
shown calcium channel blockers are first-line of drugs and are effective when used in
combination with other anti-hypertensive medications. It is as well-tolerated, especially when
combined with ACE inhibitors, but less effective when combined with diuretics because both
have natriuretic effects (Nguyen et al., 2010). JNC7 recommends CCB as first line drug for use
for high-risk cardiovascular patients and diabetes (JNC8, 2014).
Angiotensin Receptor Blockers
Angiotensin receptor blockers (ARBs) act by blocking angiotensin II from binding to its
receptors, as a result inhibiting it from causing vasoconstriction and fluid retention. ARBs are
more costly than ACE inhibitors but have similar blood pressure effects. Cost-effectiveness
analysis shows ARB proving to be more expensive to initiate than ACE. ARB can be initiated if
there is intolerance with ACE inhibitors (Nguyen et al., 2010).
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Combination Therapy
Patients with uncontrolled blood pressure may benefit from combination therapy; this
should be initiated when the target blood pressure goal is not achieved with mono therapy and
when BP is above 20/10 mm Hg. Each anti-hypertensive medication has a different mechanism
of action; using two or more anti-hypertension medications allows for applying complementary
mechanisms to lowering blood pressure effectively. Some of the benefits for fixed combination
therapy include faster response, fewer side effects from medications, and better compliance
(Nguyen et al., 2010). ACE inhibitors or ARBs combined with diuretics have shown to be
effective in lowering blood pressure and with fewer side effects in all genders. Also, the
combination therapy of CCB with ACE inhibitors is effective, but the combination of ACE
inhibitors and ARB is not preferred because it results in increased risk of side effects. Nguyen et
al., (2010) further cite studies reporting that the combination of ACE and ARB potentiates risks
of hypotension syncope, renal problem, and hyperkalamia (Nguyen et al., 2010).
Resistant Hypertension
Resistant hypertension is the failure of three anti-hypertensive medications to control a
patient’s blood pressure effectively, including a tolerated dose of diuretic. The most effective
way to manage anti-hypertensive treatment failure is to reevaluate conditions that may be
responsible for lack of blood pressure control and to develop an aggressive anti-hypertensive
treatments plan with well-tolerated doses. Some factors that may contribute to treatments failure
are BP measurement technique; white coat effect; poor compliance and inappropriate dosing; use
of non-prescribed medications, such decongestants; excessive use of alcohol; increased dietary
sodium intake; obesity; and diabetes mellitus (Nguyen et al., 2010). It is recommended that a
fourth anti-hypertensive agent be added to the treatments regimen if blood pressure is still not

MANAGEMENT OF HYPERTENSION

16

achieved. An evidence-based study has shown that adding spironolactone may be effective in
lowering BP. Patient who are obese or have sleep apnea may benefit from spironolactone and
should be considered using because of association with aldosterone excess (Nguyen et al., 2010).

Clinical Significance of Literature Review and Major Learning Points
Several researchers, (Dubrey, 2013, Yoder, Thornburg, and Bisognano, 2009, and Magee
et. al., 2001), have made clear the clinical significance for studying women of childbearing age.
The literature shows consensus that this group poses a unique challenge for clinicians with
respect to monitoring and managing hypertension. As Yoder et. al put it: “Women of
childbearing age with hypertension represent an interesting and challenging population. As a
general rule, women tend to have lower blood pressure than men. There is an age delay in the
development of hypertension such that most women do not require hypertensive therapy during
their childbearing years. However, the increasing prevalence of obesity and metabolic syndrome
can herald increased numbers of younger women presenting with hypertension.”
Clinical Significance
A listing provided by Yoder et. al. (2009, p. 891) further illustrates the consensus found
in the literature about clinical significance (the take-away message for clinicians):


Hypertension goals for women of childbearing age are the same as for other groups.



Physicians should consider reproductive goals when selecting medications.
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Hypertension during pregnancy is often a symptom of an underlying syndrome with
significant maternal and fetal morbidity and mortality.



Early recognition and prompt treatment of hypertensive disorders during pregnancy are
necessary to avoid deleterious outcomes.



Hypertensive disorders of pregnancy likely portend future cardiovascular disease.
Major Learning Points
According to Dubrey, (2013), while the guidelines for the management of hypertension

are similar in both genders, the clinical management may require considerable modification for
women of childbearing age. Therefore, careful considerations regarding hypertension treatment
goal, choice of medication for young women who are or might become pregnant, and women of
childbearing age using contraceptive or replacement therapy should always be in the clinician’s
mind.


The goal of hypertension treatment in women of childbearing age is to reduce blood
pressure to 140/90mm. Drug therapy is initiated if lifestyle modification cannot
adequately bring blood pressure to goal.



Lifestyle assessment and potential modification are the first step in hypertension
management. Education should focus on risk factors associated with hypertension,
including sedentary lifestyle, overweight, smoking, high alcohol consumption, and
salt intake.



In pregnancy-related hypertension, the risk to mother and fetus must be considered
against any potential for serious drug induced side effect. Clinician should
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discontinue ACE inhibitors and ARBs within 2 days of notification of pregnancy and
start alternatives substitutes.


Hypertension disorder is the most common medical complications in pregnancy.



Women of childbearing age require modification to hypertensive treatment related to
their ‘phase’ of life, concomitant therapies; including hormonal therapies (Dubrey,
2013).
Conclusion

This paper posed four clinical research questions about women of childbearing age. The
literature review has shown that women of childbearing age warrant special attention of the
clinician due to possible reproductive goals and potential risks of exposing unborn fetus to
harmful effects of pharmacologic treatment. The review has also identified lifestyle modification
therapy and pharmacologic guidelines for managing hypertension in women of childbearing age.
The benefits of lifestyle changes are enormous, regardless of the use of anti-hypertensive
agents. The main issue with lifestyle changes is consistency; many people do not continue to
comply with recommended changes over time. This problem must be addressed to sustain most
treatment benefits (Lindsay, 2013). Effective lifestyle changes may benefit young women by
preventing or delaying onset of hypertension, preventing the need for medical treatment in those
with stage 1 hypertension, and contributing to a reduction in blood pressure in patients already
taking anti-hypertensive medication (Lindsay, 2013). Young women of childbearing age who are
not pregnant with mild-to-moderate hypertension should be encouraged to initiate lifestyle
modifications; anti-hypertensive medications may not be necessary because of low
cardiovascular risk.
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With respect to pharmacologic treatment options, women of childbearing age with severe
hypertension should immediately commence anti-hypertension therapy to decrease the likely risk
of cardiovascular problems. Appropriate medication dosing is required to avoid potential
ischemia of maternal organs or the placenta and fetus should the women become pregnant
(Magee, 2001). If anti-hypertensive medication is required, ACE inhibitors and ARBs are
contraindicated during pregnancy. All anti-hypertensive medications have been proven not to be
teratogenic if inadvertent exposure occurs in early pregnancy. Teratogenicity may be indicated
for mid and late trimesters. There is not enough evidence to support treating non-severe
hypertension during pregnancy, though various choices of anti-hypertensive medications for
managing severe hypertension during pregnancy, Methyldopa and Beta-blockers, other than
Atenolol, are mostly used (Magee, et al 2011). Therapy initiated for severe hypertension
(160/110 mm Hg) during pregnancy should be done to avoid maternal stroke, possible eclampsia
or direct morbidity and mortality associated with hypertension—intracerebral hemorrhage and
stroke (Yoder et al. (2009, p. 895).
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